Pfizer Wins Lipitor Patent Challenge

Law360, New York (December 18, 2005, 12:00 AM EST) -- A collective sigh of relief must have been audible at Pfizer’s headquarters on Friday, after the drug maker successfully fought off a gutsy patent challenge to the world’s best-selling drug.

On Friday, the U.S. District Court for the District of Delaware rejected a challenge by Ranbaxy, the Indian generic maker, against two Pfizer patents for Lipitor.

As a result of the decision, Pfizer will be entitled to a permanent injunction prohibiting Ranbaxy from obtaining approval for or marketing its generic version of Lipitor until 2011. The...
To view the full article, register now.